GO:2001054 negative regulation of mesenchymal cell apoptotic process: Apoptosis Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001054 describes any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal cell apoptotic process.
• Mesenchymal cells include fibroblasts, myofibroblasts, mesenchymal stem cells and stromal cells, and their survival is controlled by autophagy, kinase signalling and microRNA networks.
• Autophagy proteins such as RUBCNL/PACER can repress RIPK1 kinase-dependent apoptosis and necroptosis, directly linking autophagy to negative regulation of mesenchymal cell death.
• PTEN signalling regulates dental mesenchymal stem cell function, including survival and differentiation, making it a key node in mesenchymal cell fate.
• MicroRNAs and epigenetic regulators such as EZH2 modulate mesenchymal cell apoptosis and epithelial-mesenchymal transition in fibrosis and cancer.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to test whether candidate genes causally regulate mesenchymal cell apoptosis.
Description
GO:2001054, negative regulation of mesenchymal cell apoptotic process, is a Gene Ontology biological process term that captures any mechanism that stops, prevents or reduces the frequency, rate or extent of apoptosis in mesenchymal cells. Mesenchymal cells are mesoderm-derived cells that include fibroblasts, myofibroblasts, mesenchymal stem cells and stromal cells, and their survival or death determines tissue repair, fibrosis and tumour progression. Because apoptosis of these cells is a decisive event in wound healing, organ fibrosis and cancer stroma remodelling, the pathways that negatively regulate it are of major research interest. Mechanistically, negative regulation of mesenchymal cell apoptosis is not a single reaction but a network of survival signals, autophagy checkpoints, kinase cascades and microRNA circuits. For example, the autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, showing that autophagy machinery can actively block mesenchymal cell death. PTEN-mediated signalling controls dental mesenchymal stem cell function, including survival and differentiation, and is therefore a central regulator of mesenchymal cell fate. In fibrosis and cancer, epigenetic and microRNA regulators such as EZH2 and miR-34a influence mesenchymal cell apoptosis and epithelial-mesenchymal transition, linking this GO term to human disease. For researchers, GO:2001054 provides a precise annotation target when studying survival pathways in mesenchymal cells, whether in development, wound healing, fibrosis or tumour stroma. Understanding which genes negatively regulate mesenchymal cell apoptosis helps identify therapeutic targets and interpret single-cell and functional genomics data.
negative regulation of mesenchymal cell apoptotic process At A Glance
| GO ID | GO:2001054 |
|---|---|
| GO term | negative regulation of mesenchymal cell apoptotic process |
| Ontology | biological_process |
| Synonym | negative regulation of mesenchymal cell apoptosis |
| Major function | Stops, prevents or reduces the frequency, rate or extent of apoptosis in mesenchymal cells |
| Biological context | Mesenchymal cell survival in development, wound healing, fibrosis and tumour stroma |
| Key molecular players | Autophagy proteins (RUBCNL/PACER), PTEN signalling, microRNAs and epigenetic regulators |
| Disease relevance | Fibrosis, cancer progression and radiation injury |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq and functional apoptosis assays |
What Is GO:2001054?
GO:2001054, negative regulation of mesenchymal cell apoptotic process, is defined as any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal cell apoptotic process. In other words, it is the survival side of mesenchymal cell fate: instead of describing how mesenchymal cells die by apoptosis, this term describes the molecular events that keep them alive or delay their death. The synonym negative regulation of mesenchymal cell apoptosis is used interchangeably.
Why Is negative regulation of mesenchymal cell apoptotic process Important in Cell Biology?
Negative regulation of mesenchymal cell apoptotic process is important because mesenchymal cell survival versus death controls tissue architecture and disease outcome. When this process is too weak, mesenchymal cells die and impair wound healing and tissue regeneration. When it is too strong, mesenchymal cells accumulate and drive fibrosis or support tumour progression. Therefore, genes annotated to GO:2001054 are candidate therapeutic targets and biomarkers in regenerative medicine, fibrosis and oncology.
• Controls mesenchymal stem cell survival and differentiation in regenerative medicine.
• Determines fibroblast and myofibroblast persistence in wound healing and scar formation.
• Modulates renal fibrosis after acute kidney injury through epithelial-mesenchymal transition and macrophage polarization.
• Influences cancer stroma and metastasis through microRNA-regulated mesenchymal cell survival.
• Links autophagy and necroptosis checkpoints to mesenchymal cell fate via RUBCNL/PACER and RIPK1.
• Provides annotation targets for single-cell and spatial transcriptomics of mesenchymal populations.
• Helps interpret radiation injury and mesenchymal stem cell-derived exosome microRNA effects.
• Supports drug discovery aimed at promoting or blocking mesenchymal cell apoptosis.
What Happens During negative regulation of mesenchymal cell apoptotic process?
Survival signalling upstream of apoptosis
In simple terms: Survival signals keep mesenchymal cells alive by blocking the cell death machinery.
Negative regulation of mesenchymal cell apoptosis begins with survival signalling that opposes pro-apoptotic cues. PTEN-mediated regulation of dental mesenchymal stem cell function illustrates how a single signalling node can control survival, proliferation and differentiation of mesenchymal cells. Autophagy proteins such as RUBCNL/PACER can repress RIPK1 kinase-dependent apoptosis and necroptosis, showing that autophagy-related factors act upstream to prevent mesenchymal cell death.
Autophagy and necroptosis checkpoints
In simple terms: Autophagy can act as a brake on both apoptosis and necroptosis in mesenchymal cells.
Autophagy is a key checkpoint in negative regulation of mesenchymal cell apoptosis. RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, directly linking autophagy to survival of mesenchymal cells. Autophagy and skin wound healing are closely connected, and mesenchymal cell survival during wound repair depends on balanced autophagic activity.
MicroRNA and epigenetic control
In simple terms: Small RNAs and epigenetic enzymes tune whether mesenchymal cells live or die.
MicroRNAs and epigenetic regulators modulate negative regulation of mesenchymal cell apoptosis. The MCT-1/miR-34a/IL-6/IL-6R signalling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer, indirectly influencing mesenchymal cell survival. EZH2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and M2 macrophage polarization, linking epigenetic control to mesenchymal cell fate. Regulation of cancer metastasis by microRNAs further supports microRNA-mediated control of mesenchymal cell apoptosis.
Mesenchymal stem cell-derived exosome microRNA in radiation injury
In simple terms: Exosomes from mesenchymal stem cells carry microRNAs that can protect or sensitize cells after radiation.
Mesenchymal stem cell-derived exosome microRNAs are emerging regulators in radiation injury, where they influence survival and apoptosis of target cells. This places exosomal microRNA signalling within the broader network of negative regulation of mesenchymal cell apoptotic process.
Differential RNA expression in injury models
In simple terms: Injury models reveal which RNAs change when mesenchymal cells are stressed.
Screening and identification of differential-expressed RNAs in thrombin-induced in vitro models of intracerebral hemorrhage provides a template for discovering RNAs that may negatively regulate mesenchymal cell apoptosis after injury. Such screens help prioritize candidate genes for functional CRISPR validation.
Key Genes Involved in GO:2001054 negative regulation of mesenchymal cell apoptotic process
The following genes and proteins have been experimentally linked to negative regulation of mesenchymal cell apoptotic process or to closely related mesenchymal cell survival pathways in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RUBCNL/PACER | Autophagy protein that represses RIPK1 kinase-dependent apoptosis and necroptosis | Direct negative regulator of cell death checkpoints in mesenchymal cells |
| RIPK1 | Kinase whose activity is repressed to prevent apoptosis and necroptosis | Target for testing whether autophagy blocks mesenchymal cell death |
| PTEN | Regulates dental mesenchymal stem cell function including survival and differentiation | Central node in mesenchymal stem cell fate studies |
| EZH2 | Promotes renal fibrosis via epithelial-mesenchymal transition and M2 macrophage polarization | Epigenetic regulator linked to mesenchymal cell survival in kidney injury |
| MCT-1 | Part of MCT-1/miR-34a/IL-6/IL-6R axis promoting EMT and cancer stemness | Candidate upstream regulator of mesenchymal cell survival in breast cancer |
| miR-34a | MicroRNA in MCT-1/IL-6 axis influencing EMT and stemness | MicroRNA node for negative regulation of mesenchymal cell apoptosis |
| IL-6 | Cytokine in MCT-1/miR-34a/IL-6/IL-6R signalling axis | Inflammatory mediator of mesenchymal cell survival |
| IL-6R | Receptor for IL-6 in the MCT-1/miR-34a axis | Signalling entry point for survival cues |
| MicroRNAs (general) | Regulate cancer metastasis and mesenchymal cell behaviour | Broad class of negative regulators of apoptosis |
| Exosomal microRNAs | Mesenchymal stem cell-derived exosome microRNAs in radiation injury | Therapeutic and biomarker candidates |
| Differential-expressed RNAs | RNAs altered in thrombin-induced intracerebral hemorrhage models | Discovery resource for candidate regulators |
| Autophagy machinery | Autophagy and skin wound healing | Pathway context for mesenchymal cell survival |
| Mesenchymal stem cells | Stem cell population whose survival is regulated by PTEN signalling | Cell model for GO:2001054 studies |
| Fibroblasts/myofibroblasts | Mesenchymal cells whose persistence depends on survival signalling | Wound healing and fibrosis models |
| Stromal cells | Mesenchymal cells in tumour microenvironment | Cancer stroma studies |
| Macrophage polarization factors | M2 macrophage polarization linked to mesenchymal cell survival | Immune-mesenchymal crosstalk research |
How Is negative regulation of mesenchymal cell apoptotic process Regulated?
Negative regulation of mesenchymal cell apoptotic process is controlled by autophagy checkpoints, kinase signalling and microRNA networks. RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, showing that autophagy proteins directly regulate this process. PTEN-mediated signalling regulates dental mesenchymal stem cell function, including survival and differentiation, and therefore acts as an upstream regulator. MicroRNAs such as miR-34a within the MCT-1/miR-34a/IL-6/IL-6R axis modulate EMT, cancer stemness and M2 macrophage polarization, indirectly influencing mesenchymal cell survival. EZH2-dependent epigenetic regulation promotes renal fibrosis and epithelial-mesenchymal transition, linking chromatin state to mesenchymal cell fate. Autophagy and skin wound healing further illustrate how stress-responsive pathways tune mesenchymal cell survival.
negative regulation of mesenchymal cell apoptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EZH2 | Renal fibrosis after acute kidney injury | Knockout or point-mutation in renal mesenchymal cells |
| MCT-1 | Triple-negative breast cancer EMT and stemness | Knockout in breast cancer mesenchymal stroma models |
| miR-34a | Cancer metastasis and EMT | Overexpression or knockout of microRNA in mesenchymal cells |
| PTEN | Dental mesenchymal stem cell dysfunction | Knockout or knock-in in dental mesenchymal stem cells |
| RUBCNL/PACER | Autophagy-dependent repression of apoptosis and necroptosis | Knockout and tagged knock-in in mesenchymal cell lines |
Renal fibrosis and acute kidney injury
EZH2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and activation of M2 macrophage polarization, linking negative regulation of mesenchymal cell apoptosis to kidney disease progression. When mesenchymal cells evade apoptosis, they can persist and drive fibrotic remodelling.
Cancer progression and metastasis
The MCT-1/miR-34a/IL-6/IL-6R signalling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer, and microRNAs regulate cancer metastasis, together linking mesenchymal cell survival to tumour progression. Negative regulation of mesenchymal cell apoptosis in the tumour stroma can support cancer cell growth and immune evasion.
Radiation injury and tissue repair
Mesenchymal stem cell-derived exosome microRNAs are emerging regulators in radiation injury, where they influence cell survival and apoptosis. Autophagy and skin wound healing further connect mesenchymal cell survival to tissue repair after injury.
Intracerebral hemorrhage and injury models
Screening of differential-expressed RNAs in thrombin-induced in vitro models of intracerebral hemorrhage provides a discovery framework for RNAs that may regulate mesenchymal cell apoptosis after brain injury.
From negative regulation of mesenchymal cell apoptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is gene X required to prevent mesenchymal cell apoptosis? | CRISPR knockout in mesenchymal stem cells or fibroblasts |
| Does a specific point mutation in gene X alter survival signalling? | CRISPR point-mutation knock-in |
| Does tagging gene X reveal its localization during apoptosis repression? | Tagged knock-in (e.g. fluorescent tag) |
| Does overexpression of gene X protect mesenchymal cells from apoptosis? | CRISPR overexpression or cDNA overexpression |
| Which microRNAs regulate mesenchymal cell survival? | MicroRNA overexpression and knockout libraries |
| Which RNAs change in injury-induced mesenchymal stress? | RNA-seq of thrombin-induced in vitro models |
How to Study the negative regulation of mesenchymal cell apoptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Annexin V / caspase assay | Apoptosis frequency | Testing negative regulation of mesenchymal cell apoptosis |
| RNA-seq | Differential gene expression | Discovery of candidate regulators in injury models |
| Autophagy flux assay | Autophagic activity | Testing RUBCNL/PACER and RIPK1-dependent death |
| MicroRNA profiling | MicroRNA expression changes | Studying miR-34a and exosomal microRNAs |
| Western blot | Protein levels and cleavage | Confirming apoptosis and signalling changes |
| Immunofluorescence | Protein localization | Tagged knock-in validation |
| CRISPR library screening | Gene essentiality for survival | Identifying negative regulators of apoptosis |
| Exosome isolation | Exosomal cargo | Mesenchymal stem cell-derived microRNA studies |
Apoptosis and viability assays
Functional readouts such as Annexin V staining, caspase activity assays and viability assays are used to measure whether a candidate gene negatively regulates mesenchymal cell apoptosis. These assays are typically combined with CRISPR perturbation to establish causality.
RNA-seq and differential expression screening
RNA-seq and differential-expressed RNA screening identify transcripts that change during mesenchymal cell stress or injury, as shown in thrombin-induced in vitro models of intracerebral hemorrhage. Such screens generate candidate lists for functional validation.
Autophagy and necroptosis checkpoint assays
Autophagy flux assays and necroptosis markers are used to test whether autophagy proteins such as RUBCNL/PACER repress RIPK1 kinase-dependent apoptosis and necroptosis in mesenchymal cells. These methods distinguish apoptosis from necroptosis.
MicroRNA and exosome profiling
MicroRNA profiling and exosome isolation are used to study mesenchymal stem cell-derived exosome microRNAs in radiation injury and microRNA regulation of cancer metastasis. These approaches link non-coding RNA networks to mesenchymal cell survival.
How CRISPR Can Be Used to Study GO:2001054 negative regulation of mesenchymal cell apoptotic process
Knockout
CRISPR knockout of candidate genes such as PTEN or EZH2 in mesenchymal cells can test whether they are required for negative regulation of mesenchymal cell apoptosis. Loss-of-function phenotypes are measured by apoptosis and viability assays.
Point Mutation
CRISPR point-mutation knock-in can introduce specific amino acid changes in genes such as RUBCNL/PACER or PTEN to dissect which domains are required for repressing apoptosis. This approach separates catalytic from scaffolding functions.
Knock-in
Tagged knock-in of autophagy or signalling genes allows live-cell imaging of their localization during mesenchymal cell survival. Knock-in of reporter cassettes can also monitor apoptosis pathway activation.
Overexpression
CRISPR overexpression or cDNA overexpression of microRNAs such as miR-34a or of survival genes can test whether increased dosage protects mesenchymal cells from apoptosis. Overexpression models are useful for gain-of-function studies in cancer and radiation injury.
How EDITGENE Supports negative regulation of mesenchymal cell apoptotic process Research
Researchers studying negative regulation of mesenchymal cell apoptotic process-related genes often need to determine whether a candidate gene is causally involved in mesenchymal cell survival or death. EDITGENE provides publication-ready CRISPR models and bioinformatics support to move from candidate lists to mechanistic conclusions.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of mesenchymal cell apoptotic process research.
Frequently Asked Questions About negative regulation of mesenchymal cell apoptotic process
What is GO:2001054 negative regulation of mesenchymal cell apoptotic process?
GO:2001054 is a Gene Ontology biological process term defined as any process that stops, prevents or reduces the frequency, rate or extent of mesenchymal cell apoptotic process.
What genes are involved in negative regulation of mesenchymal cell apoptosis?
Genes and proteins linked to this process include RUBCNL/PACER, RIPK1, PTEN, EZH2, MCT-1, miR-34a, IL-6 and IL-6R, as well as broader microRNA networks.
How does autophagy regulate mesenchymal cell apoptosis?
Autophagy proteins such as RUBCNL/PACER can repress RIPK1 kinase-dependent apoptosis and necroptosis, showing that autophagy acts as a brake on mesenchymal cell death.
What is the role of PTEN in mesenchymal stem cells?
PTEN-mediated regulation controls dental mesenchymal stem cell function, including survival and differentiation, making PTEN a central node in mesenchymal cell fate.
How is EZH2 linked to renal fibrosis and mesenchymal cells?
EZH2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and M2 macrophage polarization, linking epigenetic regulation to mesenchymal cell survival.
Which microRNAs regulate mesenchymal cell apoptosis?
miR-34a within the MCT-1/miR-34a/IL-6/IL-6R axis and mesenchymal stem cell-derived exosome microRNAs are examples of microRNAs that influence mesenchymal cell survival.
What research methods are used to study GO:2001054?
Common methods include Annexin V and caspase assays, RNA-seq, autophagy flux assays, microRNA profiling, Western blot, immunofluorescence and CRISPR library screening.
How can CRISPR help study negative regulation of mesenchymal cell apoptosis?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of whether a candidate gene prevents or reduces mesenchymal cell apoptosis.
Why is negative regulation of mesenchymal cell apoptosis important in cancer?
MicroRNA-regulated mesenchymal cell survival and EMT progression support cancer stemness and metastasis, making this process relevant to tumour progression.
What diseases are associated with defects in mesenchymal cell apoptosis regulation?
Renal fibrosis, triple-negative breast cancer, radiation injury and intracerebral hemorrhage models have been linked to altered mesenchymal cell survival pathways.
Conclusion
GO:2001054 negative regulation of mesenchymal cell apoptotic process is a focused biological process term that captures the survival side of mesenchymal cell fate. Its molecular basis spans autophagy checkpoints, PTEN signalling, epigenetic regulators such as EZH2 and microRNA networks, with direct implications for fibrosis, cancer and tissue repair. Because mesenchymal cell survival versus death determines disease outcome, functional CRISPR models are essential to establish causality for candidate genes. EDITGENE supports this workflow with knockout, point-mutation, knock-in, overexpression and library screening services tailored to mesenchymal cell biology.
References
- 1. Rojas-Rivera D et al.. 2024. The autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis.. Autophagy 20(11):2444-2459 PMID: 38873940
- 2. Phothichailert S et al.. 2026. PTEN-mediated regulation of dental mesenchymal stem cell function: A scoping review.. Arch Oral Biol 191:106717 PMID: 42623834
- 3. Zhou X et al.. 2023. Enhancer of zeste homolog 2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and activation of M2 macrophage polarization.. Cell Death Dis 14(4):253 PMID: 37029114
- 4. Gao L et al.. 2024. Screening and identification of differential-expressed RNAs in thrombin-induced in vitro model of intracerebral hemorrhage.. Mol Cell Biochem 479(10):2755-2767 PMID: 37943469
- 5. Weng YS et al.. 2019. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.. Mol Cancer 18(1):42 PMID: 30885232
- 6. Ren H et al.. 2022. Autophagy and skin wound healing.. Burns Trauma 10:tkac003 PMID: 35187180
- 7. Wang H et al.. 2024. Emerging role of mesenchymal stem cell-derived exosome microRNA in radiation injury.. Int J Radiat Biol 100(7):996-1008 PMID: 38776447
- 8. Chan SH et al.. 2015. Regulation of cancer metastasis by microRNAs.. J Biomed Sci 22(1):9 PMID: 25614041
